Skip to main content

View full-text article in PMC

. 2021 Jul 16;65(8):e02349-20. doi: 10.1128/AAC.02349-20

TABLE 3.

Antiviral activity of 22 and trans-14 against several DENV laboratory and clinical strains in Vero cells

Compound	EC₅₀ (μM)^a
	Laboratory strains				Clinical strains
	DENV1 Djibouti	DENV2 nGC	DENV3 H87	DENV4 dak	DENV1	DENV2	DENV3	DENV4
22	2.2 ± 0.4	2.8 ± 2.8	3.2 ± 0.5	2.7 ± 1.1	0.6 ± 0.1	0.6 ± 0.4	0.8 ± 0.5	0.8 ± 0.6
trans-14	6.0 ± 5.7	2.8 ± 1.9	3.2 ± 1.0	2.9 ± 1.3	1.1 ± 0.2	1.3 ± 0.3	0.8 ± 0.4	1.9 ± 1.7

^a

Data are averages ± SD from at least three independent experiments. EC₅₀s against the DENV2 NGC laboratory strain in Vero cells are from Table 1.